Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Forecasted Growth Rate and Market Size of the Bi-Specific MAbS Market?

The size of the bi-specific MAbS market has seen a rapid expansion in the past few years. An increase from $7.83 billion in 2024 to $9.05 billion in 2025, with a compound annual growth rate (CAGR) of 15.5% is projected. The amplified spending on healthcare, heightened funding and initiatives by the government are identified as key factors that contributed to this growth in the previous years.

Expectations are high for the bi-specific MAbS market to experience rapid expansion in the coming years. The market is projected to surge to “$14.89 billion by 2029, growing at a compound annual growth rate (CAGR) of 13.3%. This significant growth during the forecast period can be attributed to the rising incidence of cancer, an ageing population, and escalating prevalence of chronic illnesses. Key trends anticipated throughout the forecast period include technological advancement, product innovation, increased reliance on artificial intelligence, investments in targeted and combined therapy, and the formation of strategic partnerships.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3390&type=smp

Which Factor Is Shaping The Future Of The Bi-Specific MAbS Market?

The escalating incidence of cancer and other chronic illnesses is expected to fuel the expansion of the bispecific monoclonal antibodies market in the forecasted timeline. Bispecific monoclonal antibodies, designed to combat various cancers, infectious diseases, central nervous system disorders, and autoimmune disorders, are seen as more potent than monoclonal antibodies (moAbs) since they target multiple tumor antigens on the cells to halt cancer progression. For instance, the American Cancer Society (ACS), a volunteer health organization based in the US, predicts 609,820 cancer-related fatalities in the US in 2023, as stated in their 2023 Cancer Facts & Figures report. Consequently, an increasing prevalence of chronic illnesses, including cancer, is likely to drive demand for bi-specific MAbs as an effective treatment option.

The bi-specific mabs market covered in this report is segmented –

1) By Type: Catumaxomab (Removab), Blinatumomab, Duligotumab, Emicizumab, Amivantamab, Faricimab, Teclistamab

2) By Product Type: In Vivo, In Vitro

3) By Indication: Cancer, Haemophilia A, Ophthalmic

4) By End Use: Hospitals, Research Institutes, Other End-Users

Subsegments:

1) By Catumaxomab (Removab): Cancer Therapy, Targeting EpCAM and CD3

2) By Blinatumomab: Acute Lymphoblastic Leukemia (ALL) Treatment, Targeting CD19 and CD3

3) By Duligotumab: Oncology Treatments, Targeting Epidermal Growth Factor Receptor (EGFR)

4) By Emicizumab: Hemophilia A Treatment, Targeting Factor IXa and Factor X

5) By Amivantamab: Non-Small Cell Lung Cancer (NSCLC) Therapy, Targeting EGFR And MET

6) By Faricimab: Ophthalmology Treatment (Wet Age-related Macular Degeneration, Diabetic Macular Edema), Targeting Angiopoietin-2 And VEGF-A

7) By Teclistamab: Multiple Myeloma Treatment, Targeting BCMA and CD3

What Upcoming Trends Are Expected To Impact The Bi-Specific MAbS Market Globally?

Bi-specific MAbs market players are ramping up investments in key strategic endeavours such as partnerships and collaborations, with an aim to widen their product range and enhance their global reach. Strategic collaboration typically involves two or more organizations working together to realise shared objectives or aims. An illustration of this was in October 2022 when Gilead Sciences and MacroGenics, both American biopharmaceutical companies, formed an exclusive partnership to develop MGD024, a bispecific antibody targeting CD123 and CD3, using MacroGenics’ DART platform, in addition to two other bispecific research programs. As part of this collaboration, Gilead has the sole option to license MGD024, which has the capability to treat an array of hematologic malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). MGD024 is engineered to curb cytokine-release syndrome (CRS) and to facilitate intermittent dosing, which could lead to more patient-friendly treatments and better clinical results for AML and MDS patients.

Which Companies Hold The Largest Market Share In The Bi-Specific MAbS Sector?

Major companies operating in the bi-specific MAbS market include F. Hoffmann-La Roche AG, Amgen Inc, Johnson & Johnson, Sino Biological Inc, Kyowa Kirin, Zai Lab, Alphamab Oncology, Celldex Therapeutics, Biocon, EpimAb Biotherapeutics, ABL Bio, Takeda pharmaceuticals, Innovent Biologics, Merck & Co Inc, Eli Lilly Company Inc., AbbVie Inc, Bayer AG, Pfizer Inc, Novartis AG, GlaxoSmithKline, AstraZeneca, Cytiva, Bristol Myers Squibb, AbCellera, BioMarin Pharmaceuticals, Parexel, Sanofi S.A., Novo Nordisk A/S, BBI Solutions, Aspen Pharmacare, Amoun Pharmaceuticals CO Ltd, Baxter International, Cipla Medpro South Africa

https://www.thebusinessresearchcompany.com/report/bi-specific-mab-global-market-report

How Does Regional Performance Compare Across The Bi-Specific MAbS Industry?

North America was the largest region in the bi-specific MAbs market in 2024. The regions covered in the bi-specific MAbs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3390&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model